Genomictree Future Growth
Future criteria checks 5/6
Genomictree is forecast to grow earnings and revenue by 98.5% and 81% per annum respectively. EPS is expected to grow by 98.9% per annum. Return on equity is forecast to be 3.7% in 3 years.
Key information
98.5%
Earnings growth rate
98.9%
EPS growth rate
Biotechs earnings growth | 51.8% |
Revenue growth rate | 81.0% |
Future return on equity | 3.7% |
Analyst coverage | Low |
Last updated | 24 Jun 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 34,500 | 8,500 | 11,300 | 14,300 | 1 |
12/31/2025 | 19,500 | 3,300 | -5,100 | 5,900 | 1 |
12/31/2024 | 3,900 | -6,600 | -13,500 | -6,400 | 1 |
3/31/2024 | 2,537 | -8,242 | -12,639 | -12,282 | N/A |
12/31/2023 | 3,418 | -8,756 | -11,169 | -10,881 | N/A |
9/30/2023 | 4,404 | -12,826 | -12,692 | -12,136 | N/A |
6/30/2023 | 5,796 | -13,936 | -12,564 | -11,863 | N/A |
3/31/2023 | 5,794 | -21,783 | -1,147 | -176 | N/A |
12/31/2022 | 29,866 | -6,631 | 2,462 | 4,286 | N/A |
9/30/2022 | 30,830 | -4,518 | 4,451 | 6,429 | N/A |
6/30/2022 | 29,074 | -5,559 | -5,392 | 7,472 | N/A |
3/31/2022 | 30,193 | 2,674 | -15,551 | -2,991 | N/A |
12/31/2021 | 5,140 | -11,425 | -19,459 | -7,631 | N/A |
9/30/2021 | 3,099 | -9,769 | -18,491 | -6,675 | N/A |
6/30/2021 | 3,065 | -8,470 | -9,031 | -8,063 | N/A |
3/31/2021 | 1,362 | -9,158 | -14,034 | -12,065 | N/A |
12/31/2020 | 1,239 | -11,795 | -13,025 | -10,243 | N/A |
9/30/2020 | 804 | -15,392 | -20,392 | -16,903 | N/A |
6/30/2020 | 691 | -11,125 | -16,168 | -12,782 | N/A |
3/31/2020 | 266 | -9,597 | -11,732 | -8,431 | N/A |
12/31/2019 | 282 | -10,195 | -11,278 | -8,767 | N/A |
9/30/2019 | 269 | -6,097 | -3,854 | -1,406 | N/A |
12/31/2018 | 387 | -2,484 | -4,858 | -2,080 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: A228760 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).
Earnings vs Market: A228760 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: A228760 is expected to become profitable in the next 3 years.
Revenue vs Market: A228760's revenue (81% per year) is forecast to grow faster than the KR market (10.7% per year).
High Growth Revenue: A228760's revenue (81% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: A228760's Return on Equity is forecast to be low in 3 years time (3.7%).